

## PRESS RELEASE

### ***EcoVag® clinical data published***

Copenhagen, Denmark, October 1<sup>st</sup>, 2015 - Bifodan A/S, the specialized provider of innovative probiotic solutions, announces publication of results from a clinical trial indicating that its patented EcoVag® probiotic capsule has preventive effect against recurrent vaginal infections.

#### **Publication:**

Pendhakar S et al, have published the article in BMC infectious disease (2015)15:255 with the title: "Vaginal colonization by lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection".

The publication describes an open label clinical trial on 40 Scandinavian women diagnosed with Bacterial Vaginosis (BV) or VulvoVaginal Candidiasis (VVC).

#### **Results:**

Pendhakar S et al conclude that treatment with antibiotics or anti-fungal medication in combination with EcoVag® provides long-term cure against recurrent BV and recurrent VVC.

"While the positive influence of EcoVag® in reducing the risk of recurrent BV has been proven in other clinical trials, this new publication marks the first time that a similar positive relationship is established for preventing recurrent VVC. This is very encouraging and suggests that EcoVag® has a broader application and also should be recommended for use in combination with treatment with antifungals to reduce the risk of recurrent yeast infections" says Niels Peter Bak, EcoVag® Business Unit Manager.

The clinical trial also investigated vaginal colonization of lactobacilli up to the 6 months follow-up time point. It was observed that the colonization of lactobacilli in general, and the EcoVag® probiotic strains in particular was significantly higher in women that remained cured of BV than in women with re-lapse. These findings emphasize the importance of the presence of lactobacilli and Ecovag® lactobacilli in the vaginal microbiota to defend against recurrent vaginal infections.

Vaginal infections, including BV and VVC, remains an area of great concern to women's intimate health, in part due to a severe challenge with antibiotic resistance and very high re-lapse rates. The use of clinically proven vaginal probiotics, like EcoVag®, should be considered a novel and innovative approach to help address the concerns of notably BV and to help achieve high and sustainable BV cure rates" concludes Niels Peter Bak.

To learn more about EcoVag®, please visit the website; [www.ecovag.com](http://www.ecovag.com)

For further information contact:

Niels Peter Bak

Ecovag® Business Unit Manager

[npb@bifodan.com](mailto:npb@bifodan.com)

*Bifodan A/S develops and manufactures probiotic turnkey solutions for private label customers worldwide. Based just North of Copenhagen, Denmark, Bifodan delivers science based, high quality probiotic products, manufactured at our GMP approved production facility. Bifodan has a long history in the probiotic industry, as the company was founded by the first Danish dairy to launch a probiotic based fermented milk product back in 1938. Bifodan has been dedicated to research and development of innovative probiotic solutions since 1992.*